ArticleThe Journal of investigative dermatology2015

Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita.

Hiroaki Iwata et al.PubMed ↗Publisher ↗

No numbers read from the abstract.